Mesoblast (ASX:MSB): Ryoncil Revenue, FY26 Results and Clinical Progress

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Mesoblast (ASX:MSB): Ryoncil Revenue, FY26 Results and Clinical Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast (ASX:MSB) reported FY26 revenue of USD 120.3mn versus USD 17.2mn in FY25.
Ryoncil generated USD 115.2mn in FY26 net product revenue following its US commercial launch.
September-quarter Ryoncil net revenue reached USD 28mn, up 44% YoY.
Net operating cash spend declined to USD 2.3mn in 1QFY27, compared with USD 14.9mn a year earlier.

Mesoblast Limited develops allogeneic cell medicines for inflammatory conditions, with commercial activity centred on Ryoncil and clinical programs in chronic low back pain and heart failure. On 26 October 2026, Mesoblast (ASX:MSB) was quoted at AUD 1.80, up 1.41% for the trading session. Its latest financial update reported increased Ryoncil revenue and reduced operating cash expenditure, following FY26 results that recorded a substantial expansion in product sales.

Company Business

Mesoblast (ASX:MSB) develops therapies using donor-derived mesenchymal stromal cells, manufactured for administration without individually harvesting cells from recipients. Ryoncil (remestemcel-L-rknd) is approved in the United States for steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older. The condition is a serious complication of transplantation in which donor immune cells attack recipient tissues.

Commercial operations include manufacturing, treatment-centre onboarding, reimbursement arrangements and distribution to eligible transplant facilities. Mesoblast also researches additional applications for remestemcel-L, including adult graft-versus-host disease and Duchenne muscular dystrophy. Its separate rexlemestrocel-L platform is being studied in chronic low back pain and heart failure. The company maintains operations in Australia, the United States and Singapore, alongside commercial partnerships in other regions.

Recent Development

In its mid-October 2026 update, Mesoblast (ASX:MSB) reported net Ryoncil revenue of USD 28mn for the three months ended 30 September 2026, compared with USD 19mn in the corresponding period, an increase of 44% YoY. Management reported the highest number of monthly new patient starts in September following seasonal scheduling effects during July and August. The company identified 54 onboarded treatment sites as part of its commercial expansion plans.

The company also reported net operating cash spend of USD 2.3mn in 1QFY27 against USD 14.9mn in the comparable quarter, an improvement of 85%. Cash stood at approximately USD 99mn on 30 September 2026. These September-quarter figures were described as preliminary estimates subject to customary closing procedures.

In September 2026, the US Food and Drug Administration approved a new potency assay for commercial Ryoncil. The development relates to product manufacturing and quality control. Separately, Mesoblast completed treatment of 350 patients in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain during FY26.

Financial Performance and Sector Context

Mesoblast (ASX:MSB) reported FY26 total revenue of USD 120.3mn, compared with USD 17.2mn in FY25. Ryoncil net product revenue accounted for USD 115.2mn, while royalty revenue contributed approximately USD 5.1mn. FY26 gross profit reached USD 103.6mn, compared with USD 12.1mn in FY25.

The net loss narrowed to USD 57.5mn from USD 102.1mn, while research and development expenses reached USD 97.5mn against USD 34.8mn in FY25. Selling, general and administrative expenses were USD 57.3mn, up from USD 39.3mn. Net operating cash spend was USD 43.8mn for the full year, compared with USD 50.0mn in FY25. At 30 June 2026, cash and cash equivalents totalled USD 102.9mn.

The broader cell-therapy sector faces specialised manufacturing requirements, treatment-centre capacity constraints and regulatory scrutiny. Product uptake also depends on physician adoption, patient eligibility and insurance reimbursement. These factors make commercial revenue and cash consumption relevant indicators alongside clinical trial progress.

Risks to Consider

Mesoblast (ASX:MSB) remains exposed to adoption rates for Ryoncil, manufacturing costs and the expense of developing additional indications. Clinical studies can face recruitment delays, adverse findings or regulatory requests for further evidence. The company continued to report an annual net loss despite increased sales, while borrowings, cash requirements and potential financing arrangements remain relevant balance-sheet considerations.

What to Watch Next

For Mesoblast (ASX:MSB), near-term measures include quarterly Ryoncil sales, new patient starts, treatment-site activity and operating cash expenditure. Clinical milestones include enrolment in the adult graft-versus-host disease program and follow-up in the 350-patient chronic low back pain Phase 3 study. The company has indicated that top-line results from that study are expected in mid-2027. Regulatory developments for its other programs will also be relevant.

Key Insights

Mesoblast (ASX:MSB) has moved into commercial product sales, reporting materially higher FY26 revenue and a smaller annual loss. Its October update showed further year-on-year Ryoncil revenue growth and reduced net operating cash expenditure. Future reporting will establish how commercial uptake, manufacturing spending and late-stage clinical development affect its financial position.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.